Medicinal prophylaxis of deep-vein thrombosis in geriatric practice. Literature review

Revue de Geriatrie

Volumn 23, Issue 1, 1998, Pages 31-42

  Weill Engerer, S ^a   Meaume, S ^a   Moulias, R ^a  

^a HÔPITAL CHARLES FOIX   (France)

Author keywords

Deep venous thrombosis; Medicinal propylaxis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; DEEP VEIN THROMBOSIS; DOPPLER FLOWMETRY; ECONOMICS; GASTROINTESTINAL HEMORRHAGE; GERIATRICS; HUMAN; LUNG EMBOLISM; MEDICAL INFORMATION; MORBIDITY; MORTALITY; REVIEW; RISK FACTOR; SURGICAL RISK; THROMBOEMBOLISM;

EID: 0031908017     PISSN: 03977927     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. ANDERSON F , BROWNELL-WHEELER H., GOLDBERG R., et al.: A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991;151-933-938
2. BECK J , PAUKER S., GOTTLEB J., KLEIN K., KASSIRER J.: A convenient approximation of life expectancy (the Deals) II Use in medical decision making. Am J Med 1982;73:889-897.
3. BECK J., KASSIRER J., PAUKER S.: A convenient approximation of life expectancy (the Deale) II. Validation of the method. Am J Med 1982;73:883-888
4. ERIKSSON B., KALEBO P., ANTHMYR B., et al.: Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg (Am) 1991,73:484-493.
5. HAMPSON W., HARRIS R, LUCAS H , et al.: Failure of low dose heparin to prevent deep-vein thrombosis after hip-replacement arthroplasty. Lancet 1974,2:795-797.
6. GERHART T., YETT H., ROBERTSON L., et al.: Low-molecular weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. J Bone Joint Surg 1991;73-A(4):494-502.
7. MOSKOVITZ P., ELLENBERG S., FEFFER H., Kenmore P.: Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg (Am) 1978;60:1065-1069.
8. BERGQVIST D., EFSING H., HALLBOOK T., Hedlund T.: Thromboembolism after elective and post-traumatic hip surgery: a controlled prophylactic study with dextran 70 and low-dose heparin. Acta Chir Scand 1979;115.213-218
9. PINI M., SPADINI E., CARLUCCIO L., et al.: Dextran/aspirin versus heparin/dihydroergotamine in preventing thrombosis after hip fractures. J Bone Joint Surg (Br) 1985;67(2):305-309.
10. PINI M , TAGLIAFERRI A., MANOTTI C., LASAGNI F., RINALDI E., DETTORI A. Low molecular weight heparin (Alfa LHWH) compared with unfracrionated heparin in prevention of deep-vein thrombosis after hip fractures International Angiology 1989;8(3): 134-139
11. POWERS P., GENT M , JAY R., et al : A randomized trial of less intense postoperative warfarin or aspinn therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989;149(4)-771-771.
12. LASSEN M., BORRIS L., CHRISTIANSEN H.. et al.: Prevention of thromboembolism in hip fracture patients. Arch Orthop Trauma Surg 1989, 108 10-13.
13. BERGQVIST D , KETTUNEN K , FREDLIN H Thromboprophylaxis in patients with hip fracture: a prospective, randomized, comparative study between ORG 10172 and Dextran 70 Surgery 1991;109:617-622.
14. POWERS P., GENT M , KLIMEK, et al A randomized double blind trial comparing a low molecular weight heparinoid, Orgaran, with aspirin in the prevention of venous thromboembolism following surgery for hip fracture (abstract) Thromb Haemost 1993,69: 1116.
15. HOFFMANN R., KOHLER A., PLATZ, et al.: Prevention of deep-vein thrombosis (DVT) in hip surgery: low molecular weight heparin (Sandoparin) versus 3 × 5000 I.U. UF heparin. A randomised prospective study (abstract). Thromb Haemost 1993,69.1055
16. KNIFFIN W., BARON J., BARRETT J., BIRKEMEYER J., ANDERSON F.: The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994;154:861-866.
17. MANCIET G , VERGNES C., LOUVET P., et al Epidemiologie de la maladie veineuse thrombo-embolique en gériatrie. La Revue Gériatrie 1993;18(3):119-126
18. KIERKEGAARD A., NORGREN L., OLSSON C., CASTENFORS J., PERSSON G , PERSSON S : Incidence of deep vein thrombosis in bedndden non-surgical patients Acta Med Scand 1987;222:409-111.
19. McCARTHY S., TURNER J : Low-dose subcutaneous heparin in the prevention of deepvein thrombosis and pulmonary emboli following acute stroke. Age & Ageing 1986, 15(2):84-88.
20. MCCARTHY S , TURNER J , ROBERTSON D., HAWKEY C.: Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1977 800:801.
21. IBARRA-PEREZ C., LAU-CORTES E., COLMENERO-ZUBIATE S., et al.: Prevalence and prevention of deep venous thrombosis of the lower extremities in high-nsk pulmonary patients. Angiology 1988;39(6):505-513
22. PRESCOTT R., JONES D., VASILESCU C., HENDERSON J., RUCKLEY C.: Smoking and risk factors in deep venous thrombosis. Thrombosis Haemost 1978;40:128-133.
23. TAUBMAN L., SILVERSTONE F.: Autopsy proven pulmonary embolism among the institutionalised elderly. J Am Geriatr Soc 1986;34:752-756.
24. PUXTY J., HORAN M., FOX R.: Necropsies in the elderly. Lancet 1983;1262-1264.
25. FREIMAN D., SUYEMOTO J.: Frequency of pulmonary thromboembolism in man. N Engl J Med 1965;272:1278.
26. BEDFORD P , CAIRD F.: Quart J Med New Series 1956;25:407.
27. COON W., The spectrum of pulmonary embolism, twenty years later. Arch Surg 1976, 111:398.
28. TOWBIN A : Pulmonary embolism: incidence and significance. JAMA 1954;156:209.
29. KOHN R. Cause of death in very old people. JAMA 1982;247:2793.
30. JONSSON A., HALLGRIMSSON J : Comparative disease patterns in the elderly and the very old: a retrospective autopsy study. Age & Ageing 1983;12 111-117.
31. DALEN J., ALPERT J : Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17(4):259-270.
32. COON W., Epidemiology of venous thromboembolism Ann Surg 1977;186-146-164
33. JANSEN H , SCHACHNER J , HUBBARD J., HARTMAN J.: The risk of deep veinous thrombosis a computerized epidemiologic approach. Surgery 1985;101:205-212.
34. MANGION D., Pulmonary embolism - incidence and prognosis in hospitalized elderly. Postgraduate Medical Journal 1989;65 814-817
35. BUSBY W , BAYER A , PATHY J.: Pulmonary embolism in the elderly. Age & Ageing 1988;17:205-209
36. THROMBOEMBOLIC RISK FACTORS (THRIFT) CONSENSUS GROUP. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992,305:567-574
37. CONSENSUS CONFERENCE : Prevention ov venous thrombosis and pulmonary embolism JAMA 1986,256(6):744-749.
38. CRANLEY J., CANOS A . SULL W. The diagnosis of deep vein thrombosis Fallibility of clinical symptoms and signs Arch Surg 1976;111:31-36.
39. WELLS P , LENSlNG A , DAVIDSON B , PRINS M, HIRSH J., Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. Ann Intern Med 1995; 122:47-53.
40. ANTIPLATELET TRIALISTS' COLLABORATION.: Collaborative overview of randomised trials of antiplatelet therapy - III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients BMJ 1994,308:235-246.
41. COLLINS R , SCRIMGEOUR A , YUSUF S , PETO R : Reduction in fatal pulmonary embolism and venous thrombosis by postoperative administration of subcutaneous heparin. overview of results of randomized trials in general. orthopedic, and urologic surgery N Engl J Med 1988,318.1162-1173
42. GARLUND B., THE HEPARIN PROPHYLAXIS STUDY GROUP.: Randomise, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with inrcctious disease. Lancet 1996:347 1357-1361.
43. HALKIN H., GOLDBERG J., MODAN M , MODAN B . Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Annals of Internal Medicine 1982;96.561-565.
44. CADE J.: High risk of the critically ill for venous thromboembolism. Crit Care Med 1982, 10(7):448-450
45. TURPE A., HIRSH J., JAY R . et al. Double-blind randomized trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;1:523-526
46. SANDSET P., DAHL T., STIRIS M., ROSTAD B., SCHEEL B., ABILDGAARD U A double-blind randomized palcebo-controlled trial of low molecular weight hepann once daily to prevent deep-vein thrombosis in acute iaschemic stroke Semin Thromb Hemost 1990:16 (suppl):25-33.
47. PRINS M , GELSEMA R., VAN HEERDE L., DEN OTTOLANDER G.: Prophylaxis of deep venous thrombosis with a low-molecular weight heparin (Kabi 2165) in stroke patients. Haemostasis 1989:19:245-250.
48. BERN M , BOTHE A., JR. BISTRIAN B, CHAMPAGNE C., KEANE M., BLACKBURN G. Prophylaxis against central vein thrombosis with low-dose warfarin. Surgery 1986,99(2) 216-221.
49. DAHAN R., HOULBERT D , CAULIN C , et al.: Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial Haemostasis 1986:16(2):159-164.
50. FORETTE B., WOLMARK Y : Nadroparine calcique dans la prévention de la maladie thrombo-embolique chez le suiet âgé. Presse Med 1995;24:567-571.
51. BERGMANN J., NEUHART E.. A muticenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thrombosis and Haemostasis 1996,76(4) 529-534
52. JICK H., SLONE D., BORDA I., et al.: Complication of intraveinous administration oh heparin in elderly women N Engl J Med 1970,279-284-286
53. GLAZIER R , CROWELL E Randomized prospective trial of continuous vs intermittent heparintherapy JAMA 1976;236.1365-1367
54. BASU D , GALLUS A , HIRSH J A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time N engl J Med 1972,287 324-327
55. VIEWEG W , PISCATELLI R , HOUSER J., et al.: Complication of intraveinous administration oh heparin in elderly women JAMA 1970;213:1303-1306
56. MANT M , O BRIEN B., THONG K . et al : Haemorrhagic complications of heparin therapy Lancet 1977(1) 133-134
57. WALKER A . JICK H Prediction of bleeding during heparin therapy. JAMA 1980.244: 1209-12 12
58. NELSON P., MOSER K., STONER C., et al : Risk of complications during intravenous heparin therapy. West J Med 1982;136:189-197.
59. HOLM H., ABILDGAARD U., KALVENES S., Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retropentonel bleeding. Thromb Haemost 1985,53:278-281.
60. BRITO-PAIVA E., BORZYKOWSKI J , BOUVIER C.: Petites doses d'hépannes en gériatrie. Med et Hyg 1977;35 3700-3701.
61. LECHLER E., SCHRAMM W., FLOSBACH C., THE PRIME STUDY GROUP The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (Enoxaparin). Haemostasis 1996,26(suppl 2):49-56.
62. SILAGY C., MCNEIL J., DONNAN G., TONKIN A , WORSAM B., CAMPION K : Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993;54:84-89.
63. STEERING COMITEE OF THE PHYSICIANS' HEALTH STUDY RESARCH GROUP.: Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129-135
64. THE UK-TIA STUDY GROUP.. United Kingdom transcient ischaemia attack aspirin trails interim results BMJ 1988;296:316-320.
65. WEIL J., COLIN-JONES D., LANGMAN M., et al.: Prophylactic aspirin and risk of peptic ulcer bleeding BMJ 1995;310:827-830.
66. BYNUM L , WILSON J., III. Low-dose heparin therapy in the long-term management of venous thromboembolism. Am J Med 1979;67:553-556
67. HULL R., DELMORE T., GENTON E., et al.: Warfarin sodium versus lowdose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855-858
68. HULL R., DELMORE T., CARTER C , et al.: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306: 189-194.
69. HULL R., HIRSH J , JAY R., et al., Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis N Engl J Med 1982;307:1676-1681.
70. PETTY G., LENNIHAN L., MOHR J., et al : Complications of long-termanticoagulation. Ann Neurol 1988;23:570-574.
71. HULL R., RASKOB G., ROSENBLOOM D , et al., Heparin for five days as compared with ten days in the nitial treatment of proximal venous thrombosis N Engl J Med 1990;322(18) 1260-1264.
72. ALTMAN R , BOULLON F., ROUVIER J., RACA R., DE LA FUENTE L., FAVAROLO R.: Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976;72:127-129.
73. WHITE R., MCCURDY S , VON MARENSDORFF H., WOODRUFF D , IR, LEFTGOFF L . Home Prothrombin time monitoring after the initiation of warfarin therapy, a randomized, prospective study. Ann Intern Med 1989,111 730-737
74. THE BOSTON AREA ANTICOAGULATION TRIAL FOR ATRIAL FIBRILLATION INVESTIGATORS : The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
75. CONNOLLY S LAUPACIS A., GENT M., et al.: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:319-355.
76. WELLS P., LENSING A , HIRSH J., Graduated compression stockings in the prevention of postoperative venous thromboembolism A meta-analysis. Arch Intern Med, 1994,154.67-72.